Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2025-04-14 Director's Dealing
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) where company insiders report their shareholdings and changes in ownership. Based on the provided categories, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions and ownership reports by company directors and executives.
2025-04-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used to disclose insider shareholdings and changes in ownership by company directors or major shareholders. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share-related changes by an executive.
2025-04-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a standard regulatory filing in South Korea (DART system) used to disclose insider holdings and changes in ownership. This corresponds to the 'Director's Dealing' category, as it details share ownership and transactions by company executives.
2025-04-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent filing) where directors or major shareholders report changes in their shareholdings. Based on the provided categories, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-04-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and the purpose of holding (management influence) by a major shareholder (HD Investment Association) in PharmGen Science. This type of filing is a mandatory regulatory disclosure regarding significant share ownership thresholds and does not fit into specific categories like earnings releases or annual reports. Therefore, it is classified as a Regulatory Filing (RNS).
2025-04-14 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (PharmGen Science) detailing the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure regarding changes to capital structure instruments (convertible bonds) falls under 'Capital/Financing Update' as it directly relates to the company's financing activities and capital structure adjustments.
2025-04-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.